European companies can arrive at the US market with strong technology and credible early results, yet still find that the hardest part of expansion begins after the innovation itself is proven. The United States offers a large commercial opportunity and a deep pool of capital, but access is not automatic: companies must understand how US buyers make decisions, secure the right distribution and market-access relationships, and finance the work required to establish a foothold. For American investors, the opportunity is not simply to fund a European company. It is to help translate its strengths into a business that can operate successfully on both sides of the Atlantic.

The central challenge is a bridge between two commercial environments. European companies may need a clearer route to US customers and investors; US partners need to distinguish promising technology from a business that can navigate the practical demands of a new market. The most effective cross-border strategy connects capital with local knowledge, trusted introductions and a deliberate plan for adoption.

European Innovation Needs a Route to the US - Not Just a Strong Product

A promising idea is the beginning of market entry, not its completion. European founders may have developed compelling technology and established a base in their home market, but those achievements do not automatically provide the relationships or commercial infrastructure required to enter the United States. The gap can be particularly pronounced for smaller companies: they may lack the time, capital and specialist knowledge needed to identify the right US partners while continuing to build the business at home.

American investors can help close that gap by treating market access as part of the investment thesis from the outset. That means assessing not only what a product does but also who will introduce it to US customers, how the company will build credibility, and what resources are needed to move from initial interest to repeatable adoption. A US expansion plan is strongest when those questions are answered before a company commits significant time and money to entering the market.

As Ross Morton, Managing Partner at Nodenza, from the United States, highlighted, access to the US market requires more than a promising product; European healthcare companies must also build the right connections to bring their innovations to American patients. As he explained, “They often lack the network in the US to launch these products.”

The US Market Requires a Different Commercial Mindset

Cross-border expansion is not a matter of transferring a European sales approach unchanged to the United States. As Ross Morton observed, decision-making can be shaped by different incentives in the two environments. A solution that is persuasive on its merits may still struggle if the company does not understand the economic considerations that influence US purchasing, prescribing or adoption decisions. The point is not that one market values outcomes and the other does not; it is that companies must understand the incentives and decision processes operating in the market they are entering.

For European founders, adapting means testing the commercial case from the perspective of US decision-makers. Who pays? Who benefits financially or operationally? Who has authority to approve adoption? What evidence or business case will make a buyer comfortable with the change? American investors can help founders ask these questions early, refine how the value proposition is presented, and avoid mistaking positive feedback for a viable route to revenue.

Ross Morton emphasized that entering the US healthcare market involves navigating an unfamiliar business environment, where companies must adapt their strategies to local market dynamics. As he noted, “The real difficulties arise when people come to the US and realize that things are a little different.”

Capital and Investment Support Are Essential to Scaling

Market entry costs money before it reliably generates revenue. Companies may need to fund local expertise, customer discovery, market-specific planning, distribution arrangements and the time required to build trust with new buyers. A company can therefore have a credible product and still lack the resources to make the transition from a home-market business to an international one. Capital becomes especially consequential when a founder must pursue US expansion while sustaining operations in Europe.

As Nick Watkins, Co-founder and Managing Partner at White Cloud Capital, from the United Kingdom, explained, scaling into the US market often depends on a company's ability to secure both the funding and market access needed to support expansion: “The challenge for companies is how to scale, particularly when it comes to accessing major markets, especially the US, where the capital required, the complexities encountered and the costs to operate can be substantial.”

The investor opportunity is to match funding with the milestones that make expansion real. Rather than treating a US launch as a single event, companies and investors can plan for staged progress: validating the customer need, identifying the route to market, securing early commercial relationships and building evidence of adoption. That approach helps make the funding requirement visible and gives both sides a clearer way to judge progress. It also recognizes that a funding round alone cannot substitute for the operational work of entering a new market.

Albert Cot, Venture Partner at Tachyon Europe VC, from Spain, emphasized how American investors can help European companies accelerate their growth and gain access to the US market: “An American investor can help accelerate scaling, provide greater capabilities for growth, and, of course, improve access to the US market.”

Successful expansion is a coordinated effort between founders who understand the product and investors or partners who understand the destination market. European teams bring their existing knowledge, technology and experience; US-based partners can contribute local perspective, connections and a clearer view of how customers make decisions. Neither side can assume that its existing playbook will be sufficient on its own. The work is to connect the two into a single, realistic plan.

That plan should identify the target customer, the route to distribution, the market-specific requirements, the capital needed and the milestones that demonstrate progress. It should also define how decisions will be made and who is accountable for each part of the process. When those elements are aligned, US expansion becomes more than an aspiration or a sequence of introductions: it becomes a series of deliberate steps that can be tested, funded and improved.

Albert Cot also highlighted the gap between Europe's strong scientific capabilities and the resources needed to bring innovations to market, explaining that “European healthcare has excellent science, but lacks sufficient capital and the speed needed to scale up and gain market access.”

Distribution, Reimbursement and Relationships Drive Market Adoption

Knowing that the US market is attractive is not the same as knowing how to reach it. A company needs a route to the people and organizations that can evaluate, purchase, distribute or recommend its offering. Without relevant introductions, even a well-prepared business can spend considerable time searching for partners and trying to understand which relationships matter most. Distribution is not a final administrative detail; it is one of the core elements of a market-entry strategy.

Investors with strong local networks can help founders identify potential partners, understand the sequence of commercial decisions and secure early conversations that would otherwise be difficult to arrange. But introductions are only useful when they are targeted. Companies need to know which partners can reach the intended customers, what role each partner will play, and how success will be measured. The goal is to build a repeatable route to customers, rather than relying on a handful of disconnected contacts.

Nick Watkins illustrated the practical impact of limited market connections, explaining that “Expanding into new markets is frequently difficult without the right distribution partners to help companies establish a presence beyond their home market.”

New-market customers rarely assess a company in a vacuum. They look for reasons to believe that a product is dependable, relevant and supported by people who understand their needs. For companies entering the United States, early customer relationships can provide more than initial revenue: they can reveal whether the offering fits real workflows, expose gaps in the commercial plan and create references that make subsequent conversations easier.

This makes the first customers strategically important. Investors can help companies focus on credible early adopters, understand the decision-makers involved and learn what proof a potential customer needs before committing. In sectors where adoption depends on complex organizations, relationships with relevant buyers and users can be particularly influential. The aim is to build evidence through genuine use and customer value - not to rely on visibility or broad claims alone.

Ross Morton highlighted the importance of building relationships with healthcare payers and hospitals to secure reimbursement and win early customers: “Without connections to healthcare payers to secure reimbursement or to hospitals to bring in those first few customers, entering the market becomes much more difficult.”

He also noted that hospitals tend to follow one another when adopting new solutions: “Hospitals, much like venture funds, tend to follow the lead of other institutions when making decisions.”

Regulatory and Local Expertise Shape Market Entry

Entering a new country involves more than meeting technical or regulatory requirements. A company must understand the specific pathway relevant to its product and intended use, the evidence required at each stage, and the practical steps that connect permission to operate with customer access. For a European business expanding to the United States, the route may involve unfamiliar processes, additional expertise and careful sequencing. Misjudging these requirements can extend timelines and increase the amount of capital needed before revenue becomes dependable.

The broader lesson is to make US market-entry planning an early workstream, not a task postponed until the product is ready to sell. Founders and investors should identify the relevant requirements, clarify who is responsible for navigating them, and ensure that the expansion budget reflects the time and work involved. Local specialist advice can help companies understand obligations in the target market and avoid relying on assumptions drawn from their European experience. The objective is not to imply that every company follows the same route, but to ensure that each company has a route suited to its own circumstances.

Cross-border expansion also depends on knowledge that a company cannot always build quickly from a distance. Local partners can help founders understand market conventions, identify credible counterparties and ask the right questions before entering into commercial or employment arrangements. Trusted networks also improve the quality of opportunity discovery: investors need ways to find promising companies, while founders need access to people who can help them navigate an unfamiliar market.

That makes relationship-building a practical part of execution, not simply a networking exercise. Introductions should connect a company to relevant expertise and specific decisions - market entry, distribution, customer validation, investment or local legal review. Investors can add value by helping founders distinguish useful contacts from general visibility and by encouraging appropriate diligence before commitments are made.

Ross Morton emphasized the importance of having trusted local connections and legal guidance when entering a new market: “Finding someone with the right network to open doors, alongside a reliable local lawyer to handle due diligence on employment contracts and other legal matters, is essential.”

The message is direct: access opens the conversation, but sound local advice helps a company proceed responsibly. Networks are most valuable when they are paired with diligence and a clear understanding of the market the company is entering.

Cross-Border Deal Structures Can Open Doors

A company’s legal and investment structure can influence whether US investors are able or willing to participate. During the discussion, investors noted that some American funding sources have preferences shaped by the structure of the company and by US tax considerations. These preferences can affect the practical path to capital even when a European business has attractive technology or valuation. For founders, the implication is that corporate structure should be considered as part of the cross-border plan rather than treated as a last-minute administrative choice.

Restructuring or establishing a US entity is not a universal answer. It can have legal, tax, governance and operational consequences, and the right approach depends on the company and its objectives. Founders should therefore evaluate options with qualified advisers who understand both jurisdictions and the expectations of prospective investors. The goal is to create a structure that supports the intended financing and expansion strategy while preserving clarity about ownership, responsibilities and long-term plans.

A Partner at a VC, from the United States, highlighted the growing trend of European companies relocating their headquarters to the US, noting that “I'm beginning to see more European firms relocating and establishing their headquarters in the US, which is of great interest to us.”

Her comment points to a practical consideration: some US investors may be more prepared to assess a company when its structure aligns with their investment requirements. The decision, however, should be based on a clear business rationale and professional advice, not on the assumption that a US structure guarantees funding.

Conclusion: Make Market Access Part of the Investment from Day One

Bringing European companies into the United States is not simply a matter of finding a buyer or securing a round of funding. It requires a bridge between different commercial expectations, a practical understanding of market-entry requirements, access to distribution and customer relationships, and enough capital to support the transition. The discussions point to a consistent distinction: strong innovation creates the opportunity, but market knowledge and execution determine whether that opportunity can travel.

American investors are best positioned to help when they contribute more than capital alone. By connecting founders with the right local expertise, helping them understand US decision-making, supporting a realistic route to early customers and planning for the work required to scale, investors can help European businesses approach the market with greater clarity. For founders, the lesson is equally clear: build the US pathway early, validate assumptions with people on the ground and treat relationships, diligence and commercial adaptation as core parts of the expansion strategy.

The bridge between Europe and the United States is built through practical alignment. When the product, market-entry plan, capital and local relationships reinforce one another, cross-border expansion has a stronger foundation - and the distance between a promising European company and a credible US market presence becomes more manageable